Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
about
Three decades of beta-lactamase inhibitorsbeta-Lactamases in laboratory and clinical resistanceGenetic and kinetic characterization of the novel AmpC β-lactamases DHA-6 and DHA-7.Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillinBiochemical-genetic characterization and regulation of expression of an ACC-1-like chromosome-borne cephalosporinase from Hafnia alvei.Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics.Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates.Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Piperacillin/Tazobactam (ZOSYN)Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo iActivity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates.Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial.Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp.In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group.Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.Biochemical and molecular characterization of three new variants of AmpC beta-lactamases from Morganella morganii.New mutations in ADC-type β-lactamases from Acinetobacter spp. affect cefoxitin and ceftazidime hydrolysis.
P2860
Q24646623-8CD7BE0E-C231-4B60-AC1F-1E339C149230Q24669605-EBD99BAE-2BD0-44CB-BF16-71BA6DFCAD9FQ30365832-0F8D217C-68D3-4577-8E8E-F89149F592DBQ33693985-FBF874AD-FCA6-44CC-9CC9-52EB0AD77CE4Q33976690-3CB26B48-AE7F-4AA6-A52B-90E62C2849C8Q33979636-FEA8692F-8DCF-42BA-A496-2DCC6626C1D9Q34042624-B1C6797F-B6E9-41F2-BD47-4C6A85069A83Q35132672-E5C7BA46-70A9-444C-851A-180796D000DCQ35650111-82D690D4-ED44-4EF8-BCB0-08F08CB57697Q35891315-4800920A-42FA-47D5-A104-AC831FB52A3BQ36571851-D839E05B-4A31-451A-8678-BDB89123CFB8Q36625129-DB86CBB1-38EB-4997-83DE-A9BC53403E49Q37335781-7CEEAC76-64FF-4CA4-BF21-032E25B66705Q37733597-E4047988-3D55-44B5-9F18-9E0375507C90Q38777049-C387F0D2-C2C1-4A4D-BAD9-0E3AB88F902DQ39470473-34E28FA9-256B-4ACB-9C4B-BB0DF82D1586Q39865634-B299B8E3-1A31-4EF0-84E9-ECAC95CA7160Q39866597-5DB27260-AC78-4F66-915B-7AE0CA0C4515Q40352823-4CD4CE33-E2F2-4867-AE98-A4FFACDA647FQ40670277-40AD11AD-D4CA-4CFB-B004-3DE5D23E861FQ40710250-4FBFFC47-1B93-4053-B6CA-96325EFF6265Q41060499-020B11BD-7972-4244-BEAD-C5F2DA4DA5C4Q41189315-52635E48-B809-4FF8-AB17-0E3338DC57FBQ42009069-507A8E19-BAAA-48F2-AB8F-3A83C5FCB52AQ42595403-8522E965-B754-4405-B89B-9D098FFEA777Q43045719-68BEA54E-B362-4263-AE09-DA7203115E5FQ43260811-8F9250EB-CCE3-4D21-8C71-894AAF15F1AEQ54288863-58497FC2-5D95-4C57-A95D-BF07E88426E9
P2860
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@en
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@nl
type
label
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@en
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@nl
prefLabel
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@en
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@nl
P2093
P356
P1476
Interactions of tazobactam and ...... essed Class I beta-lactamases.
@en
P2093
P304
P356
10.1093/JAC/25.2.199
P407
P577
1990-02-01T00:00:00Z